Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment

Jorge Mestre-Ferrandiz, Marcin Czech, Josef S. Smolen, Paul Cornes, Matti S. Aapro, Silvio Danese, Stephen Deitch, Hannah Tyldsley, Will Foster, Pooja Shah, Mark Latymer*, Arnold G. Vulto

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Downloads (Pure)


IntroductionBiosimilars have improved access to biologic medicines; however, historical thinking may jeopardize the viability of future markets.Areas coveredAn expert panel of eight diverse European stakeholders provided insights about rethinking biosimilars and cost-savings, reducing patient access inequalities, increasing inter-market equity, and improving education. The insights reported here (Part 2) follow a study that provides perspectives on leveraging the holistic benefits of biosimilars for market sustainability based on independent survey results and telephone interviews of stakeholders from diverse biosimilar markets (Part 1). Directional recommendations are provided for payers.Expert OpinionThe panel's market maturity framework for biosimilars has three stages: 'Invest,' 'Expand' and 'Harvest.' Across market stages, re-thinking the benefits of biosimilars beyond cost-savings, considering earlier or expanded access/new indications, product innovations, and re-investment of biosimilar-generated cost-savings should be communicated to stakeholders to promote further engagement. During 'Expand' and 'Harvest' stages, development of efficient, forward-looking procurement systems and mechanisms that drive uptake and stabilize competition between manufacturers are key. Future biosimilars will target various therapy areas beyond those targeted by existing biosimilars. To ensure a healthy, accessible future market, stakeholders must align their objectives, communicate, collaborate, and coordinate via education, incentivization, and procurement, to maximize the totality of benefits.
Original languageEnglish
Pages (from-to)509-519
Number of pages11
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Issue number4
Early online date12 Feb 2024
Publication statusPublished - 2024

Bibliographical note

Publisher Copyright:
© 2024 Pfizer. Published by Informa UK Limited, trading as Taylor & Francis Group.


Dive into the research topics of 'Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment'. Together they form a unique fingerprint.

Cite this